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Abstract
The efficacy of treatment in fetuses in whom congenital Toxoplasma gondii infection had been established has been investigated using 
rhesus monkeys as a model for humans. A polymerase chain reaction has been developed for the detection of Toxoplasma gondii. Using 
this polymerase chain reaction congenital infection can be established within 2 days of receiving an amniotic fluid sample. The 
polymerase chain reaction has subsequently been used to monitor the effect of treatment on fetal infection. The results show that early 
treatment with the combination of pyrimethamine and sulfadiazine was clearly effective in reducing the number of parasites in the 
infected fetus. The parasite was no longer detectable in the amniotic fluid 10 to 13 days after treatment was started. Spiramycin, on the 
other hand, has to be administered for at least 3 weeks to achieve the same effect. Moreover, pharmacokinetic studies revealed that 
spiramycin does not reach the brain. Pyrimethamine and sulfadiazine are able to pass the blood-brain barrier. Pyrimethamine appears to 
accumulate in the brain tissue and reaches concentrations which are also effective in vitro. © 1997 Elsevier Science Ireland Ltd.
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1. Introduction
When a mother has acquired primary T. gondii infection 
during pregnancy, the fetus may become infected as well. 
The risk of fetal infection is related to the gestational stage 
at the time of maternal infection. Studies from Desmonts 
and Couvreur [1] have shown that the transmission rate 
increases from 25% to 54% to 65% after infection in the 
first, second, and third trimester, respectively. More recent­
ly, studies of Wong and Remington revealed transmission 
rates of 15%, 30%, and 60% [2], The severity of congeni­
tal infection also depends on the stage of pregnancy at 
which infection is acquired and the earlier it occurs, the
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more severe the infection [3]. T. gondii infection can cause 
non-specific symptoms such as intrauterine growth retarda­
tion, hepato-splenomegaly, purpura, and jaundice. A mi­
nority of congenitally infected fetuses will have severe 
manifestations such as hydrocephalus, microcephalus, 
chorioretinitis and intracranial calcifications and may even 
lead to death of the fetus.
Early diagnosis of fetal infection is important in order 
that an informed decision can be made about treatment or 
therapeutic abortion. However, prenatal diagnosis of 
congenital T. gondii infections was hampered by the lack 
of a reliable, sensitive and rapid diagnostic test. Serology, 
for instance, must rely solely on the presence of fetal IgM 
antibodies, because these antibodies do not cross the 
placental barrier, as do IgG antibodies. Antibody pro­
duction, however, often fails or is delayed in the fetus with 
a still developing immune system. Congenital T. gondii
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infection should therefore be proven by demonstrating the 
presence of the parasite but the diagnostic tests have their 
limitations; Microscopy is rather insensitive, detecting 
antigens is neither sensitive nor specific enough and tissue 
culture and mouse inoculation can be time consuming. In 
addition, not every laboratory is equipped with the 
facilities for tissue culture and animal research. Among the 
newer molecular techniques direct demonstration of the 
parasite by the polymerase chain reaction (PCR) showed 
the most promise. In 1989 when the experimental study 
described in the present paper was started the PCR on the 
BI-gene [4], a 35-fold repetitive gene which is specific for 
T g o n d i i  appeared to be a sensitive and specific test for the 
detection of T. gondii in the amniotic fluid [5], cerebrospi­
nal fluid and tissues of congenitally infected fetuses [6]. 
The PCR on the BI- gene, however, failed to detect T. 
gondii in amniotic fluid samples and blood samples from 
experimentally infected rhesus monkeys which were found 
positive by mouse inoculation [7]. Therefore, further 
investigations were necessary to enhance the sensitivity of 
the PCR and thus improve the prenatal diagnosis of 
congenital T. gondii infections.
Today PCR has proven to be of potential diagnostic 
value and it has become common practice to include the 
PCR for the antenatal diagnosis of congenital T. gondii 
infections. Currently, pregnant women suspected of having 
primary infection are tested serologically for the presence 
of specific IgM and IgG antibodies in the Netherlands. 
Treatment with spiramycin is initiated in most cases when 
the results obtained in serological testing are consistent 
with an infection acquired during pregnancy. Prenatal 
diagnosis of fetal infection is based on ultrasonography, 
amniocentesis and fetal blood sampling. Besides conven­
tional parasitological tests (tissue culture and mouse 
inoculation) the PCR performed on amniotic fluid is an 
important technique to establish fetal infection as has been 
found by Hohlfeld et al. [8]. However, PCR is not yet a 
standarized test and because it is still under investigation 
the use of PCR should be restricted to specialist centres
[9].
Congenital toxoplasmosis is treated with spiramycin, 
pyrimethamine and sulfadiazine, or a combination of these 
two drug regimens. The macrolide antibiotic spiramycin is 
mainly used in France. Spiramycin is given to pregnant 
women as soon as seroconversion has occurred. The 
antibiotic is known to be a safe drug during pregnancy. 
Beneficial effects of the antibiotic have been claimed. 
Placental infection is less frequently found in women 
treated with spiramycin [3,10]. A reduction in the inci­
dence of congenitally infected infants born to treated 
versus untreated mothers is found as well [3]. Although 
these findings indicate that treatment with spiramycin 
reduces the risk of fetal infection, it is not known whether 
the antibiotic prevents transmission of infection or whether 
it has also a therapeutic effect on the infected fetus. The 
latter is probably not the case since spiramycin does not
modify the pattern of clinically apparent infection in the 
fetus probably because spiramycin does not reach thera­
peutic concentrations in the fetus.
At present the synergistic combination of pyrimethamine 
and sulfadiazine is the treatment of choice for congenital 
toxoplasmosis and has been given to pregnant women for 
nearly 30 years. Several investigators report a significant 
reduction in the incidence of congenital infection after 
treatment with the pyrimethamine-sulfadiazine combina­
tion [11-13], The drug regimen appears more effective 
than spiramycin in eradicating T, gondii parasites from the 
placenta [10]. Moreover, pyrimethamine-sulfadiazine 
treatment leads to a reduction in the number of severely 
affected babies and a shift to less severe and subclinical 
forms [14], The effect of pyrimethamine-sulfadiazine has 
been claimed to be superior to spiramycin but no prospec­
tive, randomized trials have been conducted. Therefore, 
more research was needed on treatment of fetuses with 
proven congenital T. gondii infections.
1.1. Aim o f  the study
Before introduction of the PCR test, prenatal diagnosis 
of congenital T. gondii infections was unreliable and so a 
woman who acquired a primary T. gondii infection during 
pregnancy was forced to decide between treatment or 
terminating her pregnancy without knowing whether the 
fetus was infected. Moreover, clinicians could not guaran­
tee that treatment would be effective nor could they be 
reasonably sure that the fetus was infected in which case 
treatment would merely be preventive.
Therapeutic abortion in The Netherlands is legally 
permissible until 24 weeks gestation, when the rate of 
transmission to the fetus is ^15%. Thus, the choice of 
termination of pregnancy would lead to a high number of 
unnecessary abortions. It was therefore important to im­
prove the prenatal detection of T. gondii infections and 
also to conduct prospective, randomised studies on the 
effectiveness of treatment of the infected fetus.
The following items were studied:
1. How can fetal infection with T. gondii be established 
when there is serological evidence of primary infection 
in the mother?
2. What is the effect of chemotherapeutic treatment of the 
mother during gestation in the congenitally infected 
fetus ?
2. Results of the study and general discussion
A new diagnostic test was developed to improve the 
prenatal diagnosis of congenital T. gondii infections. The 
PCR method was chosen because this technique has 
already proven its applicability as a diagnostic test in a
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variety of other microbiological infections. The principle 
of a diagnostic PCR is in vitro amplification of specific 
target DNA sequences on the genome of interest (in this 
case T. gondii). This way, it is theoretically possible to 
detect a single molecule within the abundance of host 
DNA.
Initially, the PCR on the BI-gene described by Burg et 
al. [4] was chosen. The applicability of this PCR was 
tested on clinical samples in which the presence of T. 
gondii was proven by conventional diagnostic techniques, 
such as mouse inoculation, tissue culture, and/or micro­
scopy [6]. The PCR on the BI-gene, however, failed to 
detect T. gondii in amniotic fluid samples and blood 
samples from experimentally infected rhesus monkeys 
which were found positive by mouse inoculation. To 
improve the sensitivity of the PCR, a nested PCR was 
developed with the small subunit ribosomal DNA gene (ss 
rDNA) as target [15]. A nested PCR is characterised by 
performing two PCR’s subsequently, using the amplified 
product of the first reaction as the target for the second 
reaction. For the development of the nested PCR the 
complete nucleotide sequence of the ss rDNA was eluci­
dated. The rDNA gene was chosen because it contains 
several T. gondii-specific sequences. In addition, the gene 
product, the ribosomal RNA, is present in about 10,000 
copies per cell (or per parasite) and can also be used as 
target in PCR [15].
The nested PCR on the rDNA gene appeared to be more 
sensitive than mouse inoculation, and fulfilled the qualities 
of a diagnostic test for the prenatal detection of T. gondii. 
It was possible to demonstrate the presence of T. gondii 
within two days of receiving the clinical sample by using 
the PCR. Using the conventional mouse inoculation, a test 
result was obtained one to three weeks later.
The results show that the PCR is a suitable test for the 
direct demonstration of T. gondii in the congenitally 
infected fetus. With the exception of one amniotic fluid 
sample which was not available for PCR, 6 of 7 proven 
fetal infections were found positive by PCR in the rhesus 
monkeys. PCR should be added as a diagnostic tool or it 
may even replace the conventional techniques. Amniotic 
fluid samples appeared to be the clinical sample of first 
choice for the prenatal diagnosis of T. gondii infection [7].
A recent study among pregnant women with a primary 
T. gondii infection supports our finding that a PCR on 
amniotic fluid performed better than conventional 
parasitological methods for the prenatal detection of the 
parasite [8]. The investigators demonstrated congenital 
infection in all of the 34 cases, in which transmission of 
infection had occurred, by PCR. Follow-up testing, using 
the conventional methods, confirmed the presence of 
congenital toxoplasmosis [8].
The PCR is currently used as an additional diagnostic 
tool for the prenatal diagnosis of congenital T. gondii 
infection at the department of Medical Microbiology of the 
Academic Hospital “ St. Radboud” in Nijmegen.
After the investigations on the improvement of a 
diagnostic technique for the detection of T . gondii in­
fections, the study focused on the effect of treatment in the 
infected fetus when the drugs are given to the mother. 
These experiments were earned out in rhesus monkeys 
(Mcicaca mulatto) for logistic and practical reasons. More­
over, transmission of infection was expected to be similar 
for rhesus monkeys and humans because they both possess 
a placenta of the hemochorial type. The animal experi­
ments were performed after accreditation by the ethical 
committee of the Faculty of Medical Science, according to 
the Law on Animal Experimentation in The Netherlands.
The rhesus monkey seemed a suitable animal on which 
to perform these investigations. Former studies have 
shown that this monkey served well as a model for human 
congenital T. gondii infections [7]. The frequencies of 
transmission of infection which were found in the rhesus 
monkey after maternal infection in the second and third 
trimester of gestation equal those observed in humans.
The traditional therapy for congenital T. gondii in­
fections is pyrimethamine in combination with a sul­
fonamide, usually sulfadiazine. Spiramycin is less active 
than the pyrimethamine-sulfadiazine combination, but it is 
capable of inhibiting the growth of free and intracellular 
parasites, The studies focused on these two drug regimens 
since it was still unclear whether or not these anti-7bjto 
plasma  drugs reach therapeutic concentrations in already 
infected fetuses. The dosage regimen for the drugs was 
established by pharmacokinetic studies in the rhesus 
monkeys, since such data were not available for this 
animal species. Rhesus monkeys were infected in the 
second trimester of pregnancy. Treatment with anti-Toxo­
plasm a  drugs was started immediately after fetal infection 
had been proven and continued throughout pregnancy. 
Transmission of infection occurred in 5 of 8 monkeys in 
the group treated with spiramycin and in 6 of 10 monkeys 
in the group treated with pyrimethamine and sulfadiazine. 
The effect of treatment on fetal infection was monitored by 
PCR. It appeared that spiramycin reduced the number of 
parasites in the amniotic fluid to undetectable levels within 
a period of three weeks [16]. The pharmacokinetic studies 
revealed that spiramycin accumulated in the tissues of 
mother and fetus, but spiramycin was not found in the 
brain tissue [16,17]. In comparison with spiramycin pyri­
methamine in combination with sulfadiazine is more 
effective on congenital T. gondii infection. T. gondii  
parasites were no longer found in the amniotic fluid after 
10 to 13 days of treatment with pyrimethamine and 
sulfadiazine [18]. In contrast with spiramycin, both pyri­
methamine and sulfadiazine were able to cross the blood- 
brain barrier. Moreover, pyrimethamine was found to 
accumulate in the brain tissue and reaches therapeutic 
levels [19].
The pharmacokinetic studies of sulfadiazine in the 
rhesus monkey revealed the presence of 5 metabolites. 
Three of these metabolites have not (yet) been found in
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humans [19]. The metabolites appeared to be present not 
only in the urine, but in plasma as well. It was not known 
whether these metabolites possessed anti-Toxoplasma ac­
tivity and thus whether they contributed to the efficacy of 
treatment. Therefore, anti-Toxoplasma  activity of these 
metabolites has been studied in vitro [20]. Except for 
A^4-acetyl-sulfadiazine, all metabolites possess anti-Toxo- 
p  las ma activity in vitro.
The finding of metabolites of sulfadiazine in the rhesus 
monkey which are not present in humans raises the 
question whether these metabolites contribute to the effica­
cy of treatment. Pharmacokinetic studies in the rhesus 
monkey revealed that the metabolites 5-OH-glucuronide- 
sulfadiazine and 5-OH-sulphate-sulfadiazine do not con­
tribute to the efficacy of treatment, since effective serum 
concentrations are not reached [19]. The contribution of 
two other metabolites, 5-OH-sulfadiazine and 4-OH-sul- 
fadiazine, to the efficacy of treatment is rather low, since 
they appear to be present in small proportions in the 
plasma of the rhesus monkeys [19]. All together, the 
proportion of active sulfa- compounds in serum of humans 
appears to be similar to what has been found in rhesus 
monkeys. These arguments suggest that extrapolation of 
the findings in the rhesus monkey to the human situation is 
justified.
The improvement of the prenatal detection of congenital 
T. gondii infections and the effect of treatment in the 
infected fetus logically leads to the question whether there 
is a place for a routine serological screening on a primary 
infection during pregnancy or not. Acute T. gondii in­
fection in pregnant women almost always goes unre­
cognized and will continue to be missed unless a sys­
tematic antenatal toxoplasmosis screening programme is 
initiated. However, before any screening programme can 
be introduced, the benefits and risks of such a programme 
have to be thoroughly evaluated. It should also be taken 
into account that what seems appropriate for one country is 
not always appropriate for another, since the frequency of 
infection differs per geographic area. In fact, the following 
factors need to be investigated before considering such a 
screening programme:
1 . The prevalence of immunity to toxoplasmosis in 
women of childbearing age.
2. The incidence of primary infection in pregnancy
3. The rate of transmission to the fetus
4. The predictive value (sensitivity, specificity, and repro­
ducibility) of a serological screening test to diagnose a 
primary infection in the pregnant woman.
5. The reliability of diagnosing infection of the fetus.
6 . The efficacy of treatment for the fetus, when the drugs 
are given to the mother.
The items 5 and 6 are the topics of the foregoing studies, 
and they are both conditions for introduction of a serologi­
cal screening programme. Some remarks are made with 
regard to these items.
With PCR a test result can be obtained within two days 
of receiving the clinical sample. In addition, PCR is 
suitable for monitoring the effect of treatment by analysis 
of amniotic fluid before and after initiation of therapy. 
Thanks to the considerable gain of time a pregnant woman, 
suspected of a primary T. gondii infection, can await the 
test result of the PCR before taking a well considered 
decision.
Based on the findings in humans that treatment with 
spiramycin reduces the number of infected offspring, 
treatment with spiramycin might be considered for primary 
prevention (i.e. prevention of transmission of infection) 
when transmission of infection has not (yet) occurred. The 
findings in rhesus monkeys, however, do not support the 
use of spiramycin to prevent transmission of infection. 
Although spiramycin accumulates in the placenta, it never 
reaches the high concentrations that are reported to be 
necessary to inhibit T. gondii in vitro. Pyrimethamine and 
sulfadiazine on the other hand, do reach effective serum 
and tissue concentrations. In addition, with pyrimethamine 
and sulfadiazine it takes 10 to 13 days to reduce the 
number of parasites to undetectable levels in the amniotic 
fluid. It is therefore expected that it will take about the 
same time to reduce the parasite in the blood circulation of 
the mother. Based on these findings, one course of 4 weeks 
of pyrimethamine with sulfadiazine for prevention of 
transmission of infection is preferred over that with 
spiramycin. This regimen also corresponds with that for 
healthy neonates, born to women with a proven primary 
infection during pregnancy, but in whom congenital in­
fection is not definitely proven.
Treatment with spiramycin for secondary prevention 
(i.e. after transmission of infection has occurred) is only 
partially effective. It appears from the results that 
spiramycin should be administered for at least three weeks 
to reduce the number of parasites in the amniotic fluid. 
Moreover, spiramycin does not reach the brain. Spiramycin 
will not be the treatment of choice for secondary preven­
tion, since cerebral infection is the most severe conse­
quence of T. gondii infection in the fetus. The combination 
of pyrimethamine and sulfadiazine is preferred over 
spiramycin to prevent symptoms in the fetus when antenat­
al infection is proved. The results indicate that treatment 
with pyrimethamine-sulfadiazine efficiently reduces the 
number of parasites in the fetus; as mentioned before no 
parasites were detected in the amniotic fluid 10 to 13 days 
after initiation of therapy. In contrast with spiramycin, both 
pyrimethamine and sulfadiazine reach the brain tissue. 
Pyrimethamine even accumulates in the brain.
Our studies thus demonstrate that treatment with pyri­
methamine and sulfadiazine is effective in reducing the 
number of parasites in the infected rhesus monkey fetus. 
The results have been found under experimental con­
ditions, in which rhesus monkeys have been treated for 
congenital T. gondii infections with a dosage regimen that
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is also used in humans. Extrapolation of the results to the 
human situation, however, should be interpreted with care, 
since the pharmacokinetics of pyrimethamine and sul­
fadiazine in rhesus monkeys differ in some ways from the 
pharmacokinetics in humans. For instance, the serum 
elimination half lifes of both pyrimethamine and sul­
fadiazine are shorter in rhesus monkeys than in humans 
[18]. However, whether it is valid to extrapolate the effect 
of a treatment in monkeys to the human situation depends 
on the serum and tissue concentrations which are achieved 
and the period of time during which these effective 
concentrations are present.
Effective serum concentrations of pyrimethamine and 
sulfadiazine as found in rhesus monkeys appear also to be 
present in humans. In addition, the period of time during 
which these effective serum concentrations are found in 
humans is at least as long as or even longer than those 
found in the rhesus monkeys [21-23],
It must be realized that the results described here were 
obtained under experimental conditions in which the time 
of maternal infection was exactly known, prenatal de­
tection of the parasite was frequently performed to monitor 
fetal infection, and treatment was started early after fetal 
infection. This is at variance with the natural situation, in 
which maternal infection is often not recognized because 
the infection is mostly asymptomatic and serological 
screening is not routinely performed. As a consequence, a 
majority of the fetal infections will remain unrecognized or 
diagnosed too late in order to guarantee that treatment still 
will be effective.
The findings plead for early treatment of the infected 
fetus and thus plead, indirectly, for introduction of a 
screening programme for a primary T. gondii infection 
during pregnancy. Rapid diagnosis of fetal infection is 
possible with the development of a diagnostic PCR for T. 
gondii. This creates the possibility to start treatment early 
after fetal infection has occurred. Although congenital 
toxoplasmosis may be a preventable disease, the effect of 
primary prevention is expected to be not sufficient as it is 
difficult to change the behavior of pregnant women or 
women who are attempting to conceive with regard to 
taking preventive measures. This, the improvement of the 
prenatal detection of T. gondii and the knowledge that 
pyrimethamine and sulfadiazine are effective in the infec­
ted fetus are three arguments in favor of reconsidering the 
need and practical implementations of introducing a 
serological screening programme in the Netherlands. As 
long as vaccination is not yet feasible, follow up in 
serological negative women, starting before or early after 
conception, has to be reconsidered, despite the fact that it 
is recognized not to be cost-effective.
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